International Journal of Clinical Oncology

, Volume 10, Issue 3, pp 177–181 | Cite as

Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer

  • Munetaka Takekuma
  • Makoto Maeda
  • Takachika Ozawa
  • Kazuhiko Yasumi
  • Tatsuo Torizuka



Recurrent ovarian cancer is refractory and resistant to treatment in most patients, and no effective treatment for it has been established. Starting a treatment when tumors still consist of micro foci may contribute to improvement of prognosis. Therefore, the early diagnosis of relapse is important.


Among patients with epithelial ovarian cancer in whom initial treatment achieved remission between April 1998 and December 2003, those patients in whom the cancer-related antigen (CA)125 level was increased during the subsequent follow-up period, or those who showed abnormal computed tomography (CT)/magnetic resonance imaging (MRI) findings despite normal CA125 levels, were examined by 18F-fluoro-2-deoxyglucose – positron emission tomography (FDG-PET). We compared the rates of accurate diagnosis of recurrence achieved using CT/MRI, CA125, and FDG-PET in patients with a definitive diagnosis of relapse.


We investigated 29 patients with epithelial ovarian cancer. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of FDG-PET were 84.6% (22/26), 100% (3/3), 100% (22/22), 42.9% (3/7), and 86.2% (25/29), respectively. These values were higher than the corresponding values obtained using CT/MRI or CA125 levels.


FDG-PET may be very useful for identifying sites of recurrent ovarian cancer, although this procedure had a low NPV because of the high rate of false-negative findings for micro or cystic lesions.

Key words

FDG-PET Recurrent ovarian cancer CT/MRI CA125 levels 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rustin, GJS, Nelstrop, AE, Tuxen, MK,  et al. 1996Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group studyAnn Oncol7361364PubMedGoogle Scholar
  2. 2.
    Rustin, GJS, van der Burg, MEL, Berek, JS 1993Tumor markersAnn Oncol4S71S77Google Scholar
  3. 3.
    Patsner, B, Orr, JW,Jr, Mann, WJ,  et al. 1990Does serum CA125 level prior to second look laparotomy for invasive ovarian adenocarcinoma predict size of residual diseaseGynecol Oncol38373376CrossRefPubMedGoogle Scholar
  4. 4.
    Rubin, SC, Hoskins, WJ, Hakes, TB,  et al. 1989Serum CA125 Levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancerAm J Obstet Gynecol160667671PubMedGoogle Scholar
  5. 5.
    Zimny, M, Siggelkow, W, Schroder, W,  et al. 20012-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancerGynecol Oncol83310315CrossRefPubMedGoogle Scholar
  6. 6.
    Rustin, GJS, Nelstrop, A, Stilwell, J,  et al. 1992Saving obtained by CA125 measurements during therapy for ovarian carcinomaEur J Cancer287982CrossRefPubMedGoogle Scholar
  7. 7.
    Strauss, LG, Conti, PS 1991The application of PET in clinical oncologyJ Nucl Med32623648PubMedGoogle Scholar
  8. 8.
    Bar Shalom, R, Valdivia, AY, Blaufox, MD,  et al. 2000PET imaging in oncologySemin Nucl Med3150185Google Scholar
  9. 9.
    Tucker, R, Coel, M, Ko, J,  et al. 2001Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year’s experience in a clinical centerJ Clin Oncol1925042508PubMedGoogle Scholar
  10. 10.
    Rose, PG 2000Surgery for recurrent ovarian cancerSemin Oncol31723Google Scholar
  11. 11.
    Chambers, SK, Chambers, JT, Kohorn, EI,  et al. 1988Evaluation of the role of second look surgery in ovarian cancerObstet Gynecol72404408PubMedGoogle Scholar
  12. 12.
    Potter, ME, Hatch, KD, Soong, SJ,  et al. 1991Second look laparotomy and salvage therapy: a research modality only?Gynecol Oncol4439CrossRefGoogle Scholar
  13. 13.
    Young, RC 1987A second look at second look laparotomyJ Clin Oncol513111313PubMedGoogle Scholar
  14. 14.
    Friedman, JB, Weiss, NS 1991Second thoughts about second look laparotomy in advanced ovarian cancerN Engl J Med32210791080Google Scholar
  15. 15.
    Berek, JS 1992Second-Look versus second-natureGynecol Oncol4412CrossRefPubMedGoogle Scholar
  16. 16.
    Meden, H, Rath, W, Ohlmeyer, D 1990The value of preoperative diagnosis before second-look laparotomy in ovarian cancerGeburtshilfe Frauenheilkd50102105Google Scholar
  17. 17.
    Torizuka, T, Nobezawa, S, Kanno, T,  et al. 2002Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucoseEur J Nucl Med29797803CrossRefGoogle Scholar
  18. 18.
    Yen, RF, Sun, S-S, Shen, Y-Y,  et al. 2001Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancerAnticancer Res2136913694PubMedGoogle Scholar
  19. 19.
    van der Burg, MEL, van Lent, M 1995The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancerN Engl J Med332629934CrossRefPubMedGoogle Scholar
  20. 20.
    Eisenkop, SM, Friedman, RL 2000The role of second cytoreductive surgery in the treatment of patient with recurrent epithelial ovarian carcinomaCancer88144153CrossRefPubMedGoogle Scholar
  21. 21.
    Makhija, S, Sabbatini, P, Aghajanian, C,  et al. 1999Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian patients with a positive second lookGynecol Oncol792832CrossRefGoogle Scholar
  22. 22.
    Markman, M, Brady, MF, Spirtos, NM,  et al. 1998Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a gynecologic Oncology Group StudyJ Clin Oncol1626202624PubMedGoogle Scholar
  23. 23.
    Karlan, BY, Hawkins, R, Hoh, C,  et al. 1993Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-d-glucose can detect recurrent ovarian carcinomaGynecol Oncol51175181CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2005

Authors and Affiliations

  • Munetaka Takekuma
    • 1
  • Makoto Maeda
    • 1
  • Takachika Ozawa
    • 2
  • Kazuhiko Yasumi
    • 2
  • Tatsuo Torizuka
    • 3
  1. 1.Department of GynecologyHamamatsu Medical CenterHamamatsuJapan
  2. 2.Department of PathologyHamamatsu Medical CenterHamamatsuJapan
  3. 3.Positron Medical CenterHamamatsu Medical CenterHamamatsuJapan

Personalised recommendations